INTRODUCTION
Meningiomas represent the most common primitive intracranial neoplasias. 1 According to the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS), they are subdivided into 15 histotypes and into three grades of malignancy. 2 The majority of meningiomas have an indolent clinical course and are cured by surgical resection alone. However, some meningiomas may develop recurrences and even fatal outcomes after surgery. 1 Histological grade and the extent of surgical resection represent major prognostic factors in patients affected by meningiomas. [2] [3] [4] [5] Among grade II meningiomas, the atypical histotype is the most frequent and the 5-year disease-free survival (DFS) of patients affected by this neoplasia is around 50%. 6, 7 Due to their unpredictable clinical behavior, the post-surgical management of atypical meningiomas actually represents a major issue in neuro-oncology. At the moment, radiotherapy is considered to be the first-choice treatment when surgical resection is incomplete. 8 However, its benefits are unclear in cases of radical excision. 8 Finally, although several drugs have been tested, present data are insufficient to support pharmacotherapy as firstline treatment for patients with atypical meningioma. 8 The highly variable clinical behavior of atypical meningiomas may be due to the possibility that this category of tumors is too wide. Indeed, it includes both tumors more similar to grade I meningiomas and with low probability to recur, and tumors closer to grade III meningiomas and with high biological aggressiveness. For this reason, factors able to identify cases with higher probability to recur, and which could benefit from adjuvant treatments, are warranted.
Mammalian target of rapamycin (mTOR) is a serine/ threonin kinase, which acts as a downstream mediator in the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway. 9, 10 When the pathway is activated, mTOR is phosphorylated in Ser2448 (p-mTOR Ser2448) and it regulates several cellular functions, including proliferation, differentiation, tumorigenesis and angiogenesis. 11 Interestingly, m-TOR activation and up-regulation is associated with proliferation and biological aggressiveness in several tumors, including glioblastoma. 12 In recent years, investigation of mTOR signaling in human cancer has attracted researchers' attention due to the development of specific inhibitors, that is rapamycin analogues such as everolimus (Novartis, Basel, Switzerland) and temsirolimus (WyethAyerst, Collegeville, PA, USA), which have shown clinical anti-neoplastic activities in a variety of cancers. 13, 14 On this premise, the aim of this study was to analyze pmTOR Ser2448 expression in a group of atypical meningiomas and to assess its eventual correlation with clinicopathological variables, with recurrences, and with DFS as well.
MATERIALS AND METHODS
Forty-eight atypical primary meningiomas, previously analyzed by our group, 15 represented the cohort of this study.
Cases were classified as atypical based on WHO criteria. 2, 6 With regard to minor atypical criteria, we defined increased cellularity as the presence of more than 53 nuclei in the diameter of a high-power field (HPF), and macronucleoli as nucleoli visible by using a 10× objective lens and in at least 50% of the samples. 6, 15, 16 In addition, sheeting was recorded when the tumor had no whorls, lobules, syncytia or small aggregations in at least 50% of the sample. 15 Finally, spontaneous necrosis was considered in the presence of small foci involving less than half of an HPF, and showing gradual transition from the surrounding viable tumor, with a rim of pyknotic nuclei. 17 Data on the site and extent of surgical resection of the tumor and on the development of recurrences and DFS were available for all cases.
All cases had been submitted to complete surgical resection. Based on Simpson's grade, 5 they were subdivided into: grade 1 (complete excision, including dura and bone), grade 2 (complete excision plus apparently reliable coagulation of dural attachments) and grade 3 meningiomas (complete excision of the solid tumor, but insufficient dural coagulation or bone excision).
Immunohistochemistry
All cases had been formalin-fixed and paraffin-embedded for histological evaluation. Following revision of the histological slides stained with hematoxylin and eosin (HE), for each case we chose a representative paraffin block from which we cut 4 μm-thick slides for immunohistochemistry against p-mTOR Ser2448. Immunohistochemistry was performed using rabbit monoclonal antibody against m-TOR (phospho S2448) (dilution 1: 100, abcam, Cambridge, UK) and BenchMark Ultra Autostainer (Ventana Medical Systems, Inc., Tucson, AZ, USA), according to the manufacturers' instructions. Incubation without primary antibody was used as negative control, while specimens of breast carcinomas known to express p-mTOR Ser2448 were used as the positive control for the immunoreaction. Sections of leptomeninges obtained at autopsy from five fetuses at mid-gestation (17-22 weeks gestation) and from five adults were also submitted to immunohistochemical procedures against p-mTOR.
For each case, we considered the intensity of staining (IS) and the area of staining positivity (ASP) for p-mTOR. IS was scored as: 1 (weak), 2 (moderate) and 3 (strong). ASP represented the percentage of positive cells and it was scored into: 1 (5%-25% positive cells); 2 (26%-50% positive cells); 3 (51%-75% positive cells); 4 (>75% positive cells). Cases with less than 5% positive cells were considered to be negative for p-mTOR. Then, for each meningioma, we calculated an intensity distribution (ID) score by multiplying IS and ASP. The median ID score in the cohort was used to define low (ID score below cut-off ) and high (ID score above cut-off ) pmTOR immunohistochemical expression.
Statistical analyses
Fisher exact and Chi-squared tests were used to investigate the statistical correlations between p-mTOR expression and the clinicopathological parameters or recurrence. Recurrence was defined as detection of recurrent tumor by neuroradiological investigations (magnetic resonance imaging or computed tomography scan). DFS was assessed by the Kaplan-Meier method, with the date of primary surgery as the entry date and length of survival to the detection of a recurrent tumor as the end point. The Mantel-Cox log-rank test was applied to assess the strength of association between DFS and each of the parameters (age and gender of the patient, site, Simpson's grade, high mitotic count, brain invasion, minor atypical criteria, and combination of several histopathological criteria) as a single variable. Successively, a multivariate analysis (Cox regression model) was utilized to determine the independent effect of each variable on DFS.
A probability (P) value less than 0.05 was considered significant. Statistical analysis was performed using 
RESULTS
Cytoplasmic and strongly intense (IS: 3) p-mTOR Ser2448 immuno-expression was found in the meningothelial and endothelial cells in all the samples of fetal leptomeninges analyzed (Fig. 1A) . On the other hand, no p-mTOR immuno-expression was found in all adult leptomeningeal autopsy samples (Fig. 1B) .
Cytoplasmic p-mTOR immuno-expression was seen in 39/48 (81%) atypical meningiomas, with variable IS and ASP (Table 1) (Figs 2-3) . IS was homogeneous throughout each section. ID score ranged 1-12, and 7 was the median value. By using the median ID score as the cut-off to define low and high, 23 (48%) cases had low p-mTOR immuno-expression, while 25 (52%) had high p-mTOR immuno-expression. High p-mTOR immunohistochemical expression was more frequent in cases with high mitotic count, and less frequent in meningiomas classified as atypical based only on the presence of minor atypical criteria (Table 2) ; however, statistical significance was not reached (P = 0.08) ( Table 2 ). High p-mTOR expression was significantly associated with development of recurrences (P = 0.01) ( Table 2) . No significant correlations were found between p-mTOR immuno-expression and the other clinicopathological variables, including age and sex of the patients, or brain invasion, site and Simpson grade of the tumors ( Table 2) .
One of the cases classified as atypical due to only minor atypical criteria was composed of 80% rhabdoid cells. p-mTOR stain was found only in the rhabdoid cells, but not in the meningothelial component of the tumor (Fig. 2D) .
Kaplan-Meier curves demonstrated that high p-mTOR expression was significantly associated with shorter DFS in patients with atypical meningiomas (P = 0,01) (Fig. 4) . As shown in our previous study, 14 brain invasion (P = 0.001), increased mitotic activity (P = 0.011), sheeting (P = 0.0127), the simultaneous presence of sheeting and high mitotic index (P = 0.0018) and Simpson grade (P = 0.0038) were also significantly associated with shorter DFS in our cohort 14 (Table 3 ). Multivariate analysis showed that brain invasion and the co-presence of high mitotic index and sheeting (P = 0.0001) and Simpson grade (P = 0.016) were significant and independent prognostic variables for DFS in patients with atypical meningioma (Table 3) .
DISCUSSION
To the best of our knowledge, four previous studies investigated and demonstrated p-mTOR Ser2448 immunoexpression in meningiomas of all histological grades. [18] [19] [20] [21] According to those, [19] [20] [21] p-mTOR Ser2448 is expressed in grades I, II and III meningiomas, with no significant difference according to tumor grade. One study, including meningiomas of all grades, found no correlation between p-mTOR expression and the patients' overall survival. 21 Of note, in two studies on p-mTOR expression in meningiomas, immunohistochemistry had been performed in tissue microarrays; thus, information on p-mTOR expression just regarded a small portion of the tumor. 19, 20 In addition, although all of the studies included grade II meningiomas, none had focused specifically on atypical histotype or had analyzed whether p-mTOR expression is associated with clinicopathological features, recurrence or DFS in patients affected by atypical meningioma. Thus, this study aimed to clarify: (i) the frequency p-mTOR Ser2448 expression in atypical meningiomas; (ii) whether p-mTOR Ser2448 expression in atypical meningiomas is associated with clinical or histopathological characteristics; (iii) whether p-mTOR Ser2448 expression in atypical meningiomas is correlated with recurrence risk and DFS.
We found that the majority (81%) of atypical meningiomas displayed p-mTOR Ser2448 immuno-expression, and about half of the cases had high p-mTOR immunoexpression (>50% stain). Interestingly, meningothelial cells within adult non-neoplastic leptomeninges did not show any staining for this protein, while p-mTOR Ser2448 immuno-expression was seen in the endothelial and meningothelial cells of fetal leptomeninges. The expression of p-mTOR was previously analyzed in human fetal and adult tissue by Lee. 22 This author found weak immuno-expression in the adult and fetal pia mater, while he did not mention p-mTOR expression in the arachnoid. 22 However, that study relied on tissue microarray; thus, we may hypothesize that discrepancy with our results may depend upon sampling. p-mTOR Ser2448 expression in the meningothelial and endothelial cells of fetal leptomeninges, its absence in the adult leptomeninges and re-expression in meningiomas may suggest the involvement of this protein in leptomeningeal development, vasculogenesis and tumorigenesis. Further, p-mTOR role in embryogenesis and vasculogenesis has already been hypothesized. 23, 24 In addition, p-mTOR Ser2448 involvement in meningioma tumorigenesis was also suggested by in vivo and in vitro studies showing growth reduction in meningiomas or in cell lines treated with rapamycin analogues. 19 Finally, although not statistically significant, the correlation between p-mTOR Ser2448 expression and high mitotic index of atypical meningiomas seems further to indicate the involvement of this protein in meningioma growth.
Yesilöz and colleagues 20 previously found that p-mTOR
Ser2448 is present in half of skull base meningiomas and that its expression is significantly associated with AKT1 mutation, which is more frequent in tumors located in the anterior/middle skull base. However, our findings show that p-mTOR Ser2448 immuno-expression is not exclusive of skull base meningiomas, but it can also be observed in tumors at the convexity or in sagittal meningiomas. In addition, we could not find any significant association between p-mTOR Ser2448 expression and the site of atypical meningiomas in our cohort. Although p-mTOR Ser2448 immuno-expression can be stimulated by AKT1 activating mutations, 20 it can also be activated, through a mechanism independent from PI3K/AKT signaling, by the loss of tumor suppressor merlin, that is encoded by NF2. 25 Meningiomas with NF2 mutations are preferentially found at the posterior skull base or at the hemispheres. 26 Thus, in view of the various genetic mechanisms which can result in pmTOR activation, the lack of association with a peculiar tumor site is not surprising. The prognostic role of p-mTOR Ser2448 immunoexpression has been analyzed in several neoplasias, and with contrasting results. Indeed, p-mTOR Ser2448 expression is a favorable prognostic factor in gastric cancer 27 or in salivary gland carcinoma, 28 while it is associated with bad prognosis in tongue squamous cell carcinoma. 29 This study shows for the first time that high p-mTOR Ser2448 immuno-expression is significantly associated with recurrences and with lower DFS According to the images shown in the other papers, staining seems to be cytoplasmic in the study by Yesilöz and colleagues, 20 and only a few cells have nuclear stain in that by Johnson et al. 18 Whether p-mTOR Ser2448 subcellular localization may be relevant for prognosis or may be associated with peculiar cell functions still remains to be clarified.
Although it was not an independent prognostic variable for DFS at multivariate analysis, in view of its association with recurrence and DFS, p-mTOR Ser2448 immunoexpression could be useful to identify cases at higher risk of recurrence and which could benefit from adjuvant treatment.
In conclusion, this study shows that mTOR s2448 is expressed in a high percentage of atypical meningiomas, and at high levels in about half of these. High immunoexpression is not limited to atypical meningiomas with high mitotic index or brain invasion, but it is also observed in tumors classified as atypical only on minor atypical criteria. In addition, high mTOR s2448 expression is not restricted to tumors having a particular location, but it seems to be independent from tumor site. Since high mTOR s2448 expression represents a significant and negative prognostic factor in patients with atypical meningiomas, the evaluation of the immunohistochemical expression of this protein may be used to select cases to submit to adjuvant therapies and, in the meantime to spare adverse effects of those treatments in low-risk patients. Knowledge that mTOR s2448 is expressed in atypical meningiomas and not in normal leptomeninges might open the perspective to novel treatments with rapamycin analogues in patients affected by this neoplasia, following preliminary immunohistochemical demonstration of this target in their tumor. However, mTOR exists in two functionally and structurally distinct complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
30 mTORC1 mainly contains p-mTOR Ser2448, while mTORC2 was shown to be formed by m-TOR phosphorylated at Ser2481. 31 Whether mTOR Ser 2481 is expressed in atypical meningiomas still remains to be verified. However, the higher efficacy of the dual mTORC1/mTORC2 inhibitors compared to rapamycin in blocking the proliferation of meningioma cells 32 is strongly in favor of this hypothesis. Finally, this study still leaves unsolved whether p-mTOR expression is maintained in recurrent meningiomas, and whether it could represent a therapeutic target also in this setting.
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